Table 1.
Demographic and clinical characteristics of participants, overall and by calendar year of ART initiation (n = 9997)
| Period 1 | Period 2 | Period 3 | Overall | |
|---|---|---|---|---|
| (2000–2003) | (2004–2007) | (2008–2012) | (2000–2012) | |
| n = 2381 | n = 3058 | n = 4558 | n = 9997 | |
| (%) | (%) | (%) | (%) | |
| Baseline age | ||||
| 18–34 | 693 (29.1) | 791 (25.9) | 1459 (32.0) | 2943 (29.4) |
| 35–44 | 1034 (43.4) | 1297 (42.4) | 1518 (33.3) | 3849 (38.5) |
| 45–54 | 481 (20.2) | 718 (23.5) | 1145 (25.1) | 2344 (23.4) |
| 55+ | 173 (7.3) | 252 (8.2) | 436 (9.6) | 861 (8.6) |
| Sex | ||||
| Female | 480 (20.2) | 591 (19.3) | 760 (16.7) | 1831 (18.3) |
| Male | 1901 (79.8) | 2467 (80.7) | 3798 (8303) | 8166 (81.7) |
| History of IDUa | ||||
| Yes | 592 (31.0) | 719 (29.5) | 830 (23.7) | 2141 (27.3) |
| No | 1315 (69.0) | 1721 (70.5) | 2666 (76.3) | 5702 (72.7) |
| Aboriginal ancestryb | ||||
| Yes | 150 (10.6) | 151 (9.7) | 166 (9.4) | 467 (9.8) |
| No | 1266 (89.4) | 1410 (90.3) | 1599 (90.6) | 4275 (90.2) |
| CD4 cell count (cells/μL) | ||||
| <350 | 2024 (85.0) | 2679 (87.6) | 2986 (65.5) | 7689 (76.9) |
| ≥350 | 357 (15.0) | 379 (12.4) | 1572 (34.5) | 2308 (23.1) |
Analyses restricted to those with non-missing data
IDU injection drug use
a n = 7843
b n = 4742